Investors in Salix Pharmaceuticals (NASDAQ: SLXP )
might have had some upset stomachs in the days leading up to today's
announcement of positive results from the TARGET-3 study of Xifaxan in
IBS-D. Although a medical journal review from mid-2012 had suggested
that Xifaxan would pass this study of long-term retreatment, there are
hundreds of millions of high-margin incremental sales riding on Salix
ultimately securing FDA approval for a drug that has had a tough route
to approval for this large indication.
Read more here:
Why Salix Pharmaceuticals' Good Data Wasn't Great
No comments:
Post a Comment